Rosa Sandro G Viveiros, Santos Wilson C
Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.
Rev Panam Salud Publica. 2020 Mar 20;44:e40. doi: 10.26633/RPSP.2020.40. eCollection 2020.
The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus , that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.
2019年12月，世界卫生组织（WHO）获悉中国湖北省武汉市爆发了冠状病毒肺炎疫情。随后，在2020年3月12日，报告了125,048例病例和4,614例死亡。冠状病毒是一种有包膜的RNA病毒，属于冠状病毒属，分布于鸟类、人类和其他哺乳动物中。WHO已将新型冠状病毒疾病命名为COVID-19。已经开展了80多项临床试验来测试冠状病毒的治疗方法，包括一些对COVID-19的药物重新利用或重新定位。因此，我们在2020年3月对clinicaltrials.gov数据库进行了检索。检索到的研究的纳入标准为：包含clinicaltrials.gov基本标识符编号；描述参与者数量和研究周期；描述参与者的临床状况；并对感染新型冠状病毒SARS-CoV-2（2019-nCoV）的患者使用已针对任何其他疾病进行研究或批准的药物进行干预。必须强调的是，本文仅收录了clinicaltrials.gov数据库中列出的试验。我们确定了24项临床试验，涉及20多种药物，如人免疫球蛋白、干扰素、氯喹、羟氯喹、阿比多尔、瑞德西韦、法匹拉韦、洛匹那韦、利托那韦、奥司他韦、甲泼尼龙、贝伐单抗和中药。尽管药物重新利用存在一些局限性，但重新定位的临床试验可能是一种有吸引力的策略，因为它们有助于发现新的药物类别；成本较低，上市所需时间较短；并且存在用于制剂和分销的现有药品供应链。
